Drug intelligence / Profile preview

donepezil transdermal patch

Development stage: Phase 4
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Transdermal

Overview

DA-5207 is a transdermal delivery system (patch) version of donepezil hydrochloride being developed by Dong-A ST for the treatment of Alzheimer's disease. It is designed to be applied once a week, which could increase patient convenience compared to existing oral treatments. The patch formulation may also reduce side effects such as nausea and vomiting that are commonly reported with oral donepezil treatments. As an acetylcholinesterase inhibitor, it works by preventing the breakdown of acetylcholine in the brain, which is a neurotransmitter important for memory and thinking.

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on donepezil transdermal patch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil transdermal patch.

Explore the full profile